semaglutide cardiovascular outcomes
In 2023 semaglutide was the 157th most prescribed medication in the United States with over 3 million prescriptions, and new real-world data now shows it cuts major adverse cardiovascular events compared with tirzepatide. This finding comes from the first large-scale observational study presented at the 2024 EASD conference. Medical Disclaimer:
Tirzepatide Vs Semaglutide
Tirzepatide Achieves 13% Prescription Weight Loss vs Semaglutide Tirzepatide delivers a 13% total body weight loss, about 2 percentage points more than semaglutide, in real-world data over 24 months. The difference reflects higher adherence and the drug’s dual GLP-1/GIP action, offering a measurable edge for clinicians seeking durable
tirzepatide real‑world
Tirzepatide delivered markedly greater weight loss than older GLP-1 agents in 2023, translating into superior blood-glucose control and a milder side-effect profile. This outcome challenges the modest results of conventional prescription weight-loss drugs, which often fail to sustain metabolic benefits over time. Medical Disclaimer: This article is for informational purposes